Bristol-Myers Squibb Company
Heterocyclic sulfones as ROR gamma modulators

Last updated:

Abstract:

There are described ROR.gamma. modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR.gamma. Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR.gamma. Gamma activity, for example, autoimmune and/or inflammatory disorders. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

12 Oct 2017

Issue date:

2 Mar 2021